Boehringer Ingelheim gives support shots for World Rabies Day 2018September 13, 2018Merial, part of Boehringer Ingelheim (BI), announced it will donate 75,000 doses of rabies vaccine to the Global Alliance for Rabies Control (GARC) in recognition of World Rabies Day on Sept. 28. The donation is a result of the Shots for Good initiative, in which BI pledged to donate doses of rabies vaccine for every dose of Purevax, Recombitek, and Imrab vaccine purchased by participating veterinary practices from July 2 to Aug. 10, 2018. The donated vaccines will support a mass dog vaccination campaign in Madagascar to control the disease and limit the potential for reintroduction of rabies from neighboring countries. "The support of our participating veterinary practices made this donation possible," said Zach Mills, DVM, executive director of BI's U.S. Pet Veterinary Professional Services. "BI understands the importance of vaccination to the overall health of pets worldwide. With more than a decade of experience advocating for rabies prevention, the Global Alliance for Rabies Control has the infrastructure to put this donation to good use." GARC will manage the campaign in Madagascar with government veterinary services and international and local nongovernmental organizations. Established protocols will be used to plot and …
SPONSORED CONTENTCanine CHF Management approved by the FDAStudies have demonstrated increased survival time for dogs with certain types of CHF. + Learn More
FDA approves NexGard expanded label claimsAugust 22, 2018Merial, part of Boehringer Ingelheim, received approval from the U.S Food and Drug Administration to expand the label claims for NexGard (afoxolaner). The flea and tick control product is now approved to prevent Borrelia burgdorferi infections as a direct result of it killing Ixodes scapularis vector ticks, commonly called black-legged, or deer, ticks. NexGard is the first and only flea and tick product to receive FDA approval for preventing infections that cause Lyme disease by killing the vector ticks, the company stated. The approval comes just as veterinarians and pet owners in many parts of the country are being warned about the potential of an increased number of Lyme disease cases in 2018. The FDA approval is based on two well-controlled laboratory studies that showed that NexGard effectively prevented the transmission of B. burgdorfei infections after dogs were infested with wild-caught I. scapularis ticks 28 days after treatment with NexGard, said the manufacturer. "Both studies measured the transmission of B. burgdorferi to dogs after exposure to infected ticks," said Zach Mills, DVM, head of US Pet Veterinary Professional Services. "All dogs treated with NexGard tested negative for B. burgdorferi infection, demonstrating that transmission was prevented as a direct result …
Heartgard producer announces heartworm awareness campaignApril 16, 2018 Merial, now a part of Boehringer Ingelheim (BI), announced a multifaceted campaign to assist veterinarians and clinic teams in promoting the consistent use of heartworm preventive medications for their patients. The announcement follows a recent survey conducted by the company, which showed a decreased use of year-round heartworm preventive measures and a corresponding increase in instances of the disease. "After years of steady progress in reducing the numbers of heartworm-positive cases in pets, a concerning backward slide has occurred over the past few years," said Stephen Jones, DVM, past president of the American Heartworm Society. "It is commendable that the Heartgard Plus team has recognized the urgency of the situation and is moving quickly and aggressively to address this challenge." Through the initiative, Merial's team will engage with both veterinarians and pet owners to listen to the challenges they face in starting and keeping their patients/pets on heartworm preventive medications for year-round protection. From this data, best practices for encouraging consistent usage will be determined and shared with the animal care community. The first component of the campaign, Take the Paw Pledge, launches this month, with veterinarians across the country asking their clients to commit …
Boehringer Ingelheim, Merial launch Recombitek Oral BordetellaFebruary 14, 2018Merial, now part of Boehringer Ingelheim, has launched Recombitek Oral Bordetella, an oral vaccine shown to be effective against canine infectious tracheobronchitis caused by Bordetella bronchiseptica, the company reported. Clinical studies suggest that as a mucosal vaccine, it offers dogs a robust immune response after a single dose, according to the manufacturer. B. bronchiseptica, one of the primary pathogens responsible for canine infectious respiratory disease complex, is unique in its ability to evade the immune system for weeks to months. During this time, a dog that appears clinically normal could be exposing other dogs. "For many dogs, oral delivery may mean a less stressful experience without the unpleasant sneeze backs of alternative vaccines delivered through the nose," said Zach Mills, DVM, executive director of Boehringer Ingelheim's U.S. Pet Vet Veterinary Professional Services. "The packaging's flip-top vial cap allows for easy opening by veterinary staff, and the safe, needle-free pipette simplifies the vaccination process while reducing risk of injury." Recombitek Oral Bordetella is administered into the dog's buccal cavity. Recombitek vaccines are backed by the Pet Vaccines Customer Satisfaction Guarantee. Visit boehringer-ingelheim.com for more information.
